NOW APPROVED FOR THE TREATMENT OF PAH AND PH-ILD

Yutrepia™ (treprostinil) inhalation powder

EXPERIENCE THE POWER OF PROSTACYCLIN

DELIVERED WITH EASE



A guide to help you understand how YUTREPIA may help with your pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD).

INDICATION

YUTREPIA™ is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

SELECTED SAFETY INFORMATION

Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:

- Have low blood pressure
- Have or have had bleeding problems
- Have asthma or chronic obstructive pulmonary disease (COPD)
- Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

WHAT IS YUTREPIA?

YUTREPIA is an inhaled treprostinil dry powder that is indicated to improve exercise ability in patients with PAH (WHO Group 1) or in patients with PH-ILD (WHO Group 3). The active ingredient in YUTREPIA, treprostinil, is well studied and proven to be safe and effective.



Smaller particles, like YUTREPIA, have the potential to reach deep into the lungs.

YUTREPIA is delivered directly into the lungs, where it's needed

YUTREPIA is made using a novel technology that produces drug particles that have the same size and shape and are free-flowing, so they may get deep into the lungs.

In contrast to conventional dry powders, delivery of YUTREPIA powder does not depend on strong inhalation by patients to break up and disperse medication.

Inhaled treprostinil therapy is the **only** approved type of treatment for both PAH and PH-ILD

WHO = World Health Organization.

SELECTED SAFETY INFORMATION

What are the possible side effects of YUTREPIA?

This product can cause serious side effects, including:

- **Low blood pressure** (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more.
- **Bleeding problems.** This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

YUTREPIA IS DELIVERED BY AN EASY-TO-USE AND CONVENIENT LOW-EFFORT INHALER



YUTREPIA consists of a small, pocket-sized inhaler and replaceable drug capsules.

No refrigeration is needed—YUTREPIA is stored at room temperature.

The inhaler does not need to be prepared or used in a specific position, reducing the chance of making an error or spilling the drug.

The easy-to-use, low-effort inhaler has been trusted by doctors and people with lung conditions for decades.

SELECTED SAFETY INFORMATION

The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

Yutrepia™ (treprostinil) inhalation powder

100% of patients in a clinical study who switched from the TYVASO® nebulizer preferred the YUTREPIA device when asked after 4 months of use.*

*Data from the INSPIRE clinical trial: 49 out of 49 participants preferred the YUTREPIA device over the TYVASO nebulizer—40 participants strongly preferred the YUTREPIA device, and 9 preferred it.

TYVASO® is a registered trademark of United Therapeutics Corporation.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

HOW TREATMENT WITH YUTREPIA MAY HELP

In clinical studies, patients with PAH or PH-ILD who took inhaled treprostinil solution showed improvement in important clinical measures

INCREASED HOW FAR THEY COULD WALK

With inhaled treprostinil solution, most patients with PAH[†] or PH-ILD were able to walk farther in a 6-minute walk test.

REDUCED THE RISK OF PH-ILD GETTING WORSE

Patients taking inhaled treprostinil solution had 39% overall reduction in the risk of a clinical worsening event.

[†]In the clinical study for PAH, patients were also receiving up to 2 non-prostacyclin oral therapies as part of their overall treatment.

Inhaled treprostinil solution is the **only** therapy proven to help patients with PH-ILD

SELECTED SAFETY INFORMATION

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

Yutrepia™ (treprostinil) inhalation powder

KNOW THE POSSIBLE SIDE EFFECTS OF YUTREPIA

YUTREPIA was studied in patients with PAH and most side effects were generally mild to moderate in severity.

The most common side effects are:

- Cough
- Headache
- Throat irritation and pain
- Nausea
- Reddening of the face and neck (flushing)
- Fainting or loss of consciousness
- Dizziness
- Diarrhea
- Shortness of breath

This safety profile is consistent with that reported for inhaled treprostinil solution in clinical studies of patients with PAH and in separate studies of those with PH-ILD.

These are not all the possible side effects of YUTREPIA. Be sure to tell your healthcare team about any side effect that bothers you. Continue to take YUTREPIA as prescribed unless you are told to stop by your healthcare team.

Call your doctor for medical advice about side effects or if you have trouble breathing.

Talk to your healthcare team about how to manage any side effects.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

YOUR YUTREPIA DOSE CAN BE CHANGED TO MEET YOUR TREATMENT GOALS

Everybody is different. The right dose for one person may not be the right dose for another. Once you start YUTREPIA, your healthcare team will work with you to find the dose that meets your treatment goals.

YUTREPIA is available in 4 dose strengths, making it easier for your doctor to find the dose that meets your needs.

1 Yellow (26.5 mcg)	1 Green (53 mcg)	1 Blue (79.5 mcg)	1 Purple (106 mcg)

YUTREPIA should be taken 3 to 5 times per day as prescribed by your doctor. Depending on your dose, you will need to take 1 or 2 capsules. If your prescribed dose is more than 106 mcg, you will need to inhale 2 YUTREPIA capsules. Each capsule is inhaled in 2 breaths.

Two and through per capsule: YUTREPIA is taken in just 2 breaths per capsule.

SELECTED SAFETY INFORMATION

Especially tell your healthcare provider if you take:

- Medicines used to treat high blood pressure or heart disease
- Medicines that decrease blood clotting (anticoagulants)
- Water pills (diuretics)
- Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

Lopid® is a registered trademark of Pfizer Inc. Rimactane® is a registered trademark of Novartis Pharmaceuticals Corporation. Rifamate®, Rifadin®, and Rifater® are registered trademarks of Sanofi-Aventis U.S. LLC.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

Yutrepia™ (treprostinil) inhalation powder

GETTING STARTED WITH YUTREPIA

Starting YUTREPIA at a dose that's appropriate for your needs

- If you have not received prostacyclin therapy before, your doctor will start you at a low dose to see how you respond to this type of treatment
- If you are transitioning from TYVASO®, your doctor will start you at a dose that gives a comparable amount of medicine to what you currently take

Changing your dose to find the one that's right for you

Your first dose may just be a starting point. Your doctor will decide to change your dose over time (known as "titration") to find the dose that suits your needs (also known as your "target dose").

Talk to your doctor and healthcare team about any symptoms or side effects you may experience, including when you have changed your dose. Do not stop taking YUTREPIA without talking with your doctor.

SELECTED SAFETY INFORMATION

Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:

- Have low blood pressure
- Have or have had bleeding problems
- Have asthma or chronic obstructive pulmonary disease (COPD)
- Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

HOW TO TAKE YUTREPIA

YUTREPIA is delivered with ease

Please see accompanying Instructions for Use for YUTREPIA for more information about how to take YUTREPIA.

SELECTED SAFETY INFORMATION

What is YUTREPIA?

YUTREPIA is a prescription medicine used in adults to treat:

- Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. YUTREPIA can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking YUTREPIA. It is not known if YUTREPIA is safe and effective in children under 18 years of age.
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. YUTREPIA can improve the ability to exercise.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

Yutrepia™ (treprostinil) inhalation powder

SPECIALTY PHARMACY PROVIDERS ARE HERE TO HELP EVERY STEP OF THE WAY

YUTREPIA is available through specialty pharmacy providers, who can guide you through every step of the process—from your first prescription to ongoing support. Your specialty pharmacy can:





Liquidia Access™

The Liquidia ACCESS program can help eligible patients get the right support to access YUTREPIA

You may be eligible for a range of programs, including:

- A voucher program to see if the medicine is right for you
- A commercial co-pay program to help with out-of-pocket costs
- A bridge program to help with gaps in coverage
- An assistance program if you are unable to afford your treatment

Your specialty pharmacy provider can work with you to determine which program may be right for you.

Please see Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

YUTREPIA™ is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

IMPORTANT SAFETY INFORMATION

Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:

- Have low blood pressure
- Have or have had bleeding problems
- Have asthma or chronic obstructive pulmonary disease (COPD)
- Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.

Especially tell your healthcare provider if you take:

- Medicines used to treat high blood pressure or heart disease
- Medicines that decrease blood clotting (anticoagulants)
- Water pills (diuretics)
- Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of YUTREPIA?

This product can cause serious side effects, including:

- **Low blood pressure** (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more.
- **Bleeding problems.** This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

What is YUTREPIA?

YUTREPIA is a prescription medicine used in adults to treat:

- Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. YUTREPIA can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking YUTREPIA. It is not known if YUTREPIA is safe and effective in children under 18 years of age.
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. YUTREPIA can improve the ability to exercise.

The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA, Instructions for Use, and additional information at www.YUTREPIA.com or call 1-888-393-5732.

Please see accompanying Full Prescribing Information for YUTREPIA.

Yutrepia™
(treprostinil) inhalation powder

Yutrepia™
(treprostinil) inhalation powder

NOW APPROVED FOR THE TREATMENT OF PAH AND PH-ILD



Experience the power of prostacyclin therapy with YUTREPIA

- Delivered directly into the lungs, where it's needed
- Taken with an easy-to-use, low-effort inhaler
- Given at a dose that's tailored to your needs

Scan the QR code to watch a comprehensive video about the dosing and administration of YUTREPIA

SELECTED SAFETY INFORMATION

The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information for YUTREPIA.

Liquidia™

© 2025 Liquidia Technologies, Inc. YUTREPIA is a trademark of Liquidia Technologies, Inc. All other trademarks are the property of their respective owners. All rights reserved. US-YUTR-2400021 06-25